LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions
Sarcoma
Interventions
OTHER

Non-Metastatic and Resectable

"Blood Draw Timepoints:~* Before any treatment begins~* After Neo-adjuvant therapy (only if you receive this type of therapy)~* After local surgery~* After Adjuvant therapy (only if you receive this type of therapy)~* Follow up after adjuvant therapy: at Months 3, 6, 9, 12, 15, 18, and 24~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"

OTHER

Metastatic and Un-resectable

"Blood Draw Timepoints:~* Before any treatment begins~* During standard of care disease evaluation visits for up to 24 months"

OTHER

No evidence of disease, under surveillance

"Blood Draw Timepoints:~* From completion of treatment- at Months 3, 6, 9, 12, 15, 18, and 24; depending on when you enroll into the study you will start at the next timepoint in this schedule~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"

OTHER

ALT or WDLS

"Blood Draw Timepoints:~• Collect once after surgery (up to six weeks after surgery)"

Trial Locations (2)

27103

RECRUITING

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

28204

RECRUITING

Levine Cancer Institute, Charlotte

All Listed Sponsors
collaborator

Paula Takacs Foundation

UNKNOWN

lead

Wake Forest University Health Sciences

OTHER

NCT06958107 - LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients | Biotech Hunter | Biotech Hunter